Skip to content

Therapeutic Effects of Endoscopic Ablation of Hunner Lesions in Interstitial Cystitis/ Bladder Pain Syndrome Patients

Therapeutic Effects of Endoscopic Ablation of Hunner Lesions in Interstitial Cystitis/ Bladder Pain Syndrome Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03468530
Enrollment
442
Registered
2018-03-16
Start date
2012-08-01
Completion date
2025-07-18
Last updated
2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Cystitis

Brief summary

efficacy of endoscopic ablation of Hunner lesions in patients with IC/BPS and the characteristics of HLs based on a long-term follow-up

Interventions

PROCEDURETransurethral ablation

transurethral resection and/or coagulation with a bipolar loop under spinal or general anesthesia

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male and female aged 18 yrs or greater 2. Patients diagnosed with BPS(Bladder Pain Syndrome) 3. Symptom persisted more than 6 months 4. Pain VAS ≥4 5. O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) scores 12 or greater with pain and nocturia domain scores \> 2. 6. Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF) \>13 7. No history of cystoscopy within 2yrs.

Exclusion criteria

1. History of augmentation cystoplasty or previous transurethral coagulation/resection due to BPS 2. Child-bearing potential, pregnant or nursing women. 3. Mean voided volume lesser than 40ml or over than 400ml. 4. Hematuria exceeds 1+ in the urinary dipstick (dipstick) examination. 5. Urinary tract infection during run-in periods. 6. Genitourinary tuberculosis or bladder,urethral and prostate cancer 7. Recurrent urinary tract infection 8. History of hysterectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal delivery or Cesarean section,prostate operation or treatment etc within 6months. 9. Neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism etc.-

Design outcomes

Primary

MeasureTime frame
change in recurrence-free survival time after ablation treatmentEvery three months for one year

Secondary

MeasureTime frame
changes in mean number of nocturia episodesEvery three months for one year
changes in mean number of urgency episodesEvery three months for one year
Change score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q)Every three months for one year
changes in mean number of daytime frequency episodesEvery three months for one year
Change score of Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF)Every three months for one year
Change score of Brief Pain Inventory-short form (BPI-sf)Every three months for one year
Occurrence of adverse eventEvery three months for one year
Score of Global Response Assessment (GRA), Patient Global Assessment (PGA) scoreevery 3months for one year

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026